Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Giving combination chemotherapy together with rituximab and yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells. PURPOSE: This phase II trial is studying giving combination chemotherapy followed by rituximab and yttrium Y 90 ibritumomab tiuxetan to see how well it works in treating patients with relapsed stage II, stage III, or stage IV follicular non-Hodgkin lymphoma.
Timeline
- Start
- 2006-05-15
- Primary completion
- 2018-10-15
- Completion
- 2018-10-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 40 mg | Intravenous |
| Subject | In Zevalin | Unknown | 185 mbq | Intravenous |
| Subject | Methylprednisolone | Other / unclassified | 250 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Y Zevalin | Protein / enzyme biologic | 11.1 mbq/kg | Intravenous |
| Subject | Y Zevalin | Protein / enzyme biologic | 14.8 mbq/kg | Intravenous |